The Conversion Gap: Why Funded Innovation Ecosystems Still Fail to Produce Scaled Companies

Most regions no longer have a funding problem in the way they describe it. They have federal awards, philanthropic commitments, state appropriations, university research budgets, and at least one venture vehicle with a regional mandate. What they do not have is a system that reliably turns those dollars into companies that reach revenue, raise institutional capital, and stay.

The gap between capital availability and capital conversion is the defining operating failure of the current innovation economy. It is structural, not motivational. Everyone in the chain is working hard on the correct portion of the problem, and the portions do not connect.

Availability is not conversion

Availability is a stock question: how much capital exists within reach of this region, this institution, this company. Conversion is a flow question: how much of that capital gets deployed against a milestone that changes what the company can do next.

Those are measured differently, owned by different people, and reported on different cycles. An economic development office measures dollars announced. A university measures awards received. A fund measures capital committed. A company measures runway. None of those metrics answers whether a technology moved from a lab position to a purchasable product.

A dollar that arrives without a defined job is a reporting event, not a capital event.

Where the drop-off actually happens

In practice, conversion fails at four handoffs. Each one is a boundary between organizations that have different clocks, different incentives, and different definitions of readiness.

1. 01

   Research to translation

   A technical result is publishable long before it is investable. The translation decision requires a market and regulatory read that the research team is not staffed to produce and the tech transfer office is not resourced to produce at scale. So the default is to wait for someone to ask.

2. 02

   Translation to program

   Accelerators and translation programs recruit on availability rather than stage fit. A cohort ends up spanning three orders of magnitude of readiness, so the curriculum optimizes for the median and advances no one at the edges.

3. 03

   Program to procurement or first customer

   The hardest handoff, and the least staffed. Health systems, agencies, and primes have procurement tempos, security requirements, and evidence thresholds that no demo day addresses. Companies exit programs prepared to pitch and unprepared to be bought.

4. 04

   Company to institutional capital

   By the time a company reaches an institutional investor, the diligence file it needs — cap table integrity, regulatory pathway, evidence plan, security posture, defensible use of proceeds — has never been assembled. The round slips on documentation, not on the technology.

Activity metrics conceal operating failure

Every one of those handoffs can fail while the dashboard stays green, because the dashboard measures the activity on either side of the boundary rather than the crossing itself.

• Companies served counts entries, not advancement.
• Events held counts throughput of the calendar, not of the pipeline.
• Dollars announced counts intent, not deployment.
• Jobs pledged counts a projection, not a payroll.

This is not dishonesty. Activity metrics are what funders historically required, what reporting systems were built to capture, and what staff were hired to produce. The problem is that they are now being used to make renewal decisions they were never designed to inform — and the moment a funder shifts to outcome-based review, a program with a decade of clean activity reporting has no evidence to submit.

What functioning conversion systems measure

Systems that convert share a small number of measurement habits. None of them are exotic; all of them require someone with the authority to enforce a gate.

1. 01

   Stage transitions, not stage occupancy

   The unit of measurement is the crossing: how many companies moved from pre-clinical to first-in-human, from prototype to paid pilot, from pilot to procurement contract, in what median time.

2. 02

   Capital deployed against named risks

   For each tranche, which technical, regulatory, or commercial risk it was responsible for removing — and whether it did.

3. 03

   Follow-on capital with attribution discipline

   Follow-on raises tracked, with an honest statement of the program's contribution rather than an implied causal claim.

4. 04

   Time-to-decision inside the system

   How long a company waits on the institution: licensing terms, gate reviews, partner introductions. Institutional latency is a conversion cost that never appears in a report.

5. 05

   Evidence readiness as a standing state

   Whether the diligence file exists today, not whether it can be assembled when an investor asks.

The operating consequence

Closing a conversion gap is rarely a strategy exercise. The strategy is usually correct on paper. What is missing is an accountable operator who owns the crossings — who can hold a gate closed, sequence a capital partner into the right moment, and refuse a submission that is not ready.

That is a role, not a document. Regions and institutions that build it stop reporting activity and start reporting conversion, usually within a single funding cycle. The ones that do not will keep announcing capital that never arrives at a company in a usable form.